Advertisement
Advertisement
March 17, 2026
Thrombolex Secures Financing for Commercialization of Bashir Catheters for Pulmonary Embolism Treatment
March 17, 2026—Thrombolex, Inc., a commercial-stage developer of a differentiated pharmacomechanical lysis platform for the treatment of pulmonary embolism and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed and supported by current investors and cofounders.
According to the company, the financing strengthens its capital position as it expands its United States commercial infrastructure and advances the generation of clinical evidence across its endovascular catheter platform. Thrombolex’s FDA-cleared Bashir endovascular catheter systems are designed to enable rapid thrombus reduction by integrating mechanical clot engagement with targeted, thrombolytic delivery, stated the company.
As part of the financing, the company announced the following new members of its Board of Directors: Keegan Harper, who is a serial entrepreneur, former CEO of Bolt Medical, and newly appointed Executive Chairman of Thrombolex; Sam Liang, a global healthcare executive with operational expertise in radiology and interventional businesses; David Bonita, General Partner of OrbiMed; and Clay DeMarcus, Principal of OrbiMed.
Advertisement
Advertisement
